Related Experiment Video

Updated: May 23, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Pharmacologic and nonpharmacologic therapies for stroke prevention in nonvalvular atrial fibrillation

Jiangli Han1, Jie Cheng, Nilesh Mathuria

  • 1Texas Heart Institute/St.Luke's Episcopal Hospital, Houston, Texas 77030, USA.

Pacing and Clinical Electrophysiology : PACE
|March 29, 2012
PubMed

Insights

Vitamin K antagonists like warfarin prevent stroke in atrial fibrillation (AF) but have risks. Newer anticoagulants and left atrial appendage (LAA) closure offer improved stroke prevention strategies for AF patients.

Area of Science:

  • Cardiology
  • Neurology
  • Pharmacology

Background:

  • Thromboembolism is a primary cause of ischemic stroke in patients with atrial fibrillation (AF).
  • Vitamin K antagonists (VKAs), such as warfarin, are established anticoagulants for stroke prevention in AF.
  • Warfarin use is limited by bleeding risks, drug/food interactions, and monitoring requirements.

Purpose of the Study:

  • To review novel pharmacotherapies for stroke prevention in AF patients.
  • To discuss nonpharmacologic approaches for stroke risk reduction in AF.
  • To compare the efficacy and safety of new anticoagulants versus warfarin.

Main Methods:

  • Review of large randomized trials comparing novel oral anticoagulants (NOACs) with warfarin.
  • Analysis of studies investigating nonpharmacologic interventions for left atrial appendage (LAA) closure.
  • Evaluation of surgical, epicardial, and endovascular LAA closure techniques.

Main Results:

  • NOACs (e.g., dabigatran, rivaroxaban) demonstrate superiority over warfarin in stroke prevention for nonvalvular AF.
  • Nonpharmacologic LAA closure methods are under investigation for patients unsuitable for anticoagulation.
  • Emerging treatments offer diverse options for managing stroke risk in AF.

Conclusions:

  • Novel anticoagulants represent a significant advancement in stroke prevention for AF.
  • LAA closure techniques provide alternative strategies for specific AF patient populations.
  • This review details current and emerging therapeutic options for AF-related stroke prevention.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...